CCDC167 as a potential therapeutic target and regulator of cell cycle-related networks in breast cancer
Master regulator
DOI:
10.18632/aging.202382
Publication Date:
2021-01-10T12:51:01Z
AUTHORS (17)
ABSTRACT
According to cancer statistics reported in 2020, breast constitutes 30% of new cases diagnosed American women. Histological markers are expressions the estrogen receptor (ER), progesterone (PR), and human epidermal growth factor (HER)-2. Up 80% cancers grouped as ER-positive, which implies a crucial role for development. Therefore, identifying potential therapeutic targets investigating their downstream pathways networks extremely important drug development these patients. Through high-throughput technology bioinformatics screening, we revealed that coiled-coil domain-containing protein 167 (CCDC167) was upregulated different types tumors; however, CCDC167 still remains unclear. Integrating many kinds databases including ONCOMINE, MetaCore, IPA, Kaplan-Meier Plotter, found high expression levels predicted poor prognoses Knockdown attenuated aggressive proliferation. We also demonstrated treatment with fluorouracil, carboplatin, paclitaxel, doxorubicin resulted decreased suppressed MCF-7 cells. Collectively, findings suggest has target cancer.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (68)
CITATIONS (24)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....